8-K: Oncotelic Secures $275K in Convertible Note Offering

Oncotelic Therapeutics, Inc. completed the initial tranche of a private placement, issuing convertible notes and warrants to raise capital for its operations.

Summary

• Oncotelic Therapeutics, Inc. completed the first tranche of a private placement offering on December 4, 2025.
• The company issued 11 units, each priced at $25,000, totaling $275,000 in gross proceeds from this tranche.
• Each unit includes a $25,000 convertible note with a 12% annual interest rate, due two years after the final closing.
• Notes are convertible into 250,000 shares of Oncotelic Common Stock at $0.10 per share or 25,000 shares of EdgePoint AI, Inc. Common Stock at $1.00 per share.
• Each unit also includes 250,000 warrants to purchase Oncotelic Common Stock at $0.12 per share or 25,000 warrants to purchase EdgePoint Common Stock at $1.25 per share, exercisable for two years.
• The offering targets accredited investors and up to 35 non-accredited investors, with a minimum of 10 units required for the offering to become effective.
• Existing 2023 PPM Note investors can exchange their notes for new units, extend prior warrants by two years, and convert EdgePoint shares (issued at $1.00) into Oncotelic Common Stock at a 1:10 ratio ($0.10 per Oncotelic share).
• The company engaged J.H. Darbie & Co., Inc. as the exclusive placement agent, incurring a $25,000 due diligence fee, a 2% ongoing diligence fee, a 13% fee on gross proceeds from JHD customers, and warrants to purchase 10% of the aggregate units sold.
• The company has committed not to conduct financings on more favorable terms for one year without the placement agent's consent.
• A Registration Rights Agreement was entered into, granting certain registration rights for the shares issued and issuable upon warrant exercise.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding for the company's operations, which is a positive. However, the high cost of capital (12% interest, significant placement agent fees, and warrants) and the substantial potential for dilution are notable negatives. The offering also highlights the company's reliance on external financing and the speculative nature of the investment.

Positives

• Successfully raised $275,000 in capital through the initial tranche of the offering, providing funds for operations.
• The offering structure provides flexibility for investors to convert into either Oncotelic or its subsidiary EdgePoint AI, Inc. common stock.
• Existing 2023 PPM Note investors are offered favorable terms, including the extension of prior warrants and a beneficial conversion rate for EdgePoint shares into Oncotelic shares (1:10).
• The company will file a registration statement to allow for the resale of the underlying shares, potentially improving liquidity for investors.

Negatives

• The offering involves significant dilution for existing shareholders due to the issuance of convertible notes and warrants.
• High costs associated with the capital raise, including a $25,000 due diligence fee, a 2% ongoing diligence fee, a 13% placement agent fee on gross proceeds, and warrants for 10% of units sold to the placement agent.
• The 12% annual interest rate on the convertible notes is relatively high, increasing the company's debt servicing costs.
• The company has committed not to conduct financings on more favorable terms for one year without the placement agent's consent, potentially limiting future financing flexibility.
• The securities are restricted and there is no public market for the units, notes, or warrants, limiting immediate liquidity for investors.

Risks

• Investment in the company involves a high degree of risk, suitable only for qualified persons with substantial financial resources.
• The company cannot assure that all 500 units of the offering will be sold, which could adversely affect its operations and financial condition, especially given no current commitment for other financing.
• The underlying securities (notes, warrants, and common stock) are restricted and may not be resold publicly except in compliance with Rule 144 or unless subsequently registered, and there is no guarantee of a readily tradable market even after registration.
• The company's ability to issue shares upon conversion or exercise is subject to maintaining sufficient authorized but unissued shares and obtaining necessary corporate actions and stockholder approvals.
• Potential for further dilution if all units are sold and all notes and warrants are converted/exercised.
• The company is subject to various federal and state securities laws and regulations, and non-compliance could lead to material adverse effects.

Future Outlook

The company plans to keep the offering open for additional closings, aiming to sell up to 500 units. It will also file a registration statement to allow for the resale of the underlying securities, with an expected effectiveness date within 120-150 days of the final closing date. The offering period for the minimum 10 units can be extended to June 30, 2026, if agreed upon by the company and the placement agent.

Management Comments

• Oncotelic Therapeutics, Inc. has caused this Common Stock Purchase Warrant to be duly executed as of the date first above written. By: Vuong Trieu, President and Chief Executive Officer.
• Oncotelic Therapeutics, Inc. has caused this Note to be executed on its behalf by an officer thereunto duly authorized as of the date set forth above. By: Vuong Trieu, President and CEO.
• Oncotelic Therapeutics, Inc. By: Vuong Trieu, Chief Executive Officer.

Industry Context

This capital raise is typical for a biotechnology company like Oncotelic Therapeutics, Inc., which often relies on private placements and convertible debt to fund research, development, and operational expenses. The offering structure, including convertible notes and warrants, is a common mechanism to attract investors in the speculative biotech sector, offering potential upside through equity conversion while providing a fixed income component. The involvement of a subsidiary (EdgePoint AI, Inc.) also suggests a strategy to diversify or leverage assets within the broader technology and healthcare landscape.

Stakeholder Impact

• Shareholders: Existing shareholders face significant potential dilution from the conversion of notes and exercise of warrants. The capital raise, however, provides funding for company operations, which could support long-term value if successful.
• Investors in the Offering: These investors gain exposure to Oncotelic and/or EdgePoint AI, Inc. with a fixed income component (12% notes) and equity upside through conversion and warrants. They also benefit from registration rights for liquidity.
• Employees: Securing capital helps ensure the company's continued operations, potentially stabilizing employment.
• Creditors: The convertible notes add to the company's debt obligations, but the capital raised could improve the company's overall financial stability.

Next Steps

• Continue the private placement offering to sell the remaining units (up to 500 total).
• File a registration statement with the SEC to cover the resale of the Registrable Securities (shares from note conversion and warrant exercise).
• Ensure the registration statement becomes effective within 120-150 days of the final closing date.
• Manage the conversion of notes and exercise of warrants as they occur, including the issuance of shares and handling anti-dilution adjustments.

Key Dates

Recommendation

The capital raise is a necessary step for Oncotelic Therapeutics, Inc. to fund its operations and advance its strategic objectives, which is a positive for the company's continuity. However, the terms of the offering, including a high 12% interest rate on convertible notes, substantial fees to the placement agent (15% of gross proceeds plus warrants), and significant potential for dilution from the conversion of notes and exercise of warrants, represent a considerable cost of capital. While the funding is crucial, the dilutive nature and high expenses temper the immediate positive impact. Investors should 'hold' to monitor the company's utilization of these funds and progress on its strategic initiatives, weighing the benefits of secured financing against the costs and potential dilution.

Keywords

Oncotelic Therapeutics, OTLC, Private Placement, Convertible Notes, Warrants, Capital Raise, Equity Financing, SEC Filing, EdgePoint AI, Accredited Investors, Dilution, Registration Rights